Fulcrum Therapeutics (FULC) Hisse Özeti
Klinik aşamada bir biyofarmasötik şirketi olan Fulcrum Therapeutics, Inc. Amerika Birleşik Devletleri'nde karşılanmamış tıbbi ihtiyacın yüksek olduğu alanlarda genetik olarak tanımlanmış hastalıkları olan hastaların yaşamlarını iyileştirmek için küçük moleküller geliştirmektedir. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 2/6 |
| Gelecekteki Büyüme | 0/6 |
| Geçmiş Performans | 0/6 |
| Finansal Sağlık | 6/6 |
| Temettüler | 0/6 |
FULC Community Fair Values
Create NarrativeSee what 7 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Fulcrum Therapeutics, Inc. Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | US$6.57 |
| 52 Haftanın En Yüksek Seviyesi | US$15.74 |
| 52 Haftanın En Düşük Seviyesi | US$5.88 |
| Beta | 3.01 |
| 1 Aylık Değişim | -16.20% |
| 3 Aylık Değişim | -39.67% |
| 1 Yıllık Değişim | 2.02% |
| 3 Yıllık Değişim | 125.77% |
| 5 Yıllık Değişim | -26.43% |
| Halka arzdan bu yana değişim | -51.33% |
Son Haberler & Güncellemeler
Analiz Makalesi • Apr 01
Fulcrum Therapeutics (NASDAQ:FULC) Is In A Good Position To Deliver On Growth Plans
We can readily understand why investors are attracted to unprofitable companies. By way of example, Fulcrum...
Yeni Anlatı • Mar 20
Fetal Hemoglobin Induction Will Reshape Sickle Cell Care And Broaden Long Term Hematology Potential
Catalysts About Fulcrum Therapeutics Fulcrum Therapeutics is a clinical stage biopharmaceutical company focused on small molecule treatments for genetically defined diseases, with an emphasis on sickle cell disease and hematologic conditions. What are the underlying business or industry changes driving this perspective?Recent updates
Analiz Makalesi • Apr 01
Fulcrum Therapeutics (NASDAQ:FULC) Is In A Good Position To Deliver On Growth Plans
We can readily understand why investors are attracted to unprofitable companies. By way of example, Fulcrum...Yeni Anlatı • Mar 20
Fetal Hemoglobin Induction Will Reshape Sickle Cell Care And Broaden Long Term Hematology Potential
Catalysts About Fulcrum Therapeutics Fulcrum Therapeutics is a clinical stage biopharmaceutical company focused on small molecule treatments for genetically defined diseases, with an emphasis on sickle cell disease and hematologic conditions. What are the underlying business or industry changes driving this perspective?
Yeni Anlatı • Mar 04
Oral Fetal Hemoglobin Induction Will Reshape Severe Sickle Cell Treatment Over The Long Term
Catalysts About Fulcrum Therapeutics Fulcrum Therapeutics is a clinical stage biopharmaceutical company focused on developing oral fetal hemoglobin inducers for sickle cell disease and other hemoglobinopathies. What are the underlying business or industry changes driving this perspective?Seeking Alpha • Feb 26
Fulcrum: Strong HbF Signal, Narrow TAM, Same 'Hold' Conclusion
Summary Fulcrum Therapeutics pivots to pociredir for severe sickle cell disease after discontinuing losmapimod. Pociredir’s Phase 1 PIONEER data shows 7/12 patients hitting the ≥20% HbF threshold, but mean HbF just misses the mark. FULC’s valuation is tied almost entirely to pociredir, with a risk-adjusted NPV of $136 million and $352.3 million in cash. I maintain a cautious 'Hold' rating; upside is limited by actual TAM and risk profile despite potential for accelerated approval. Read the full article on Seeking AlphaAnaliz Makalesi • Sep 25
We're Not Very Worried About Fulcrum Therapeutics' (NASDAQ:FULC) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, Fulcrum Therapeutics...Analiz Makalesi • Apr 04
Fulcrum Therapeutics, Inc.'s (NASDAQ:FULC) Business And Shares Still Trailing The Industry
You may think that with a price-to-sales (or "P/S") ratio of 1.7x Fulcrum Therapeutics, Inc. ( NASDAQ:FULC ) is a stock...Analiz Makalesi • Dec 23
There's Reason For Concern Over Fulcrum Therapeutics, Inc.'s (NASDAQ:FULC) Massive 34% Price Jump
Fulcrum Therapeutics, Inc. ( NASDAQ:FULC ) shareholders have had their patience rewarded with a 34% share price jump in...Analiz Makalesi • Nov 08
We Think Fulcrum Therapeutics (NASDAQ:FULC) Can Easily Afford To Drive Business Growth
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Analiz Makalesi • Sep 13
Some Confidence Is Lacking In Fulcrum Therapeutics, Inc. (NASDAQ:FULC) As Shares Slide 62%
Fulcrum Therapeutics, Inc. ( NASDAQ:FULC ) shareholders that were waiting for something to happen have been dealt a...Seeking Alpha • Sep 12
Fulcrum Therapeutics: Tough Day As Losmapimod FSHD Phase 3 Misses Badly
Summary Fulcrum Therapeutics, Inc.'s stock plummeted over 60% after its lead candidate, losmapimod, failed to meet primary and secondary endpoints in a Phase 3 study for FSHD. Despite prior optimism and significant investments from Sanofi and positive analyst ratings, the REACH trial's results were disappointing, leading to the suspension of the losmapimod program. Fulcrum's management, facing leadership changes and a challenging market, will now focus on its other clinical-stage candidate, pociredir, for sickle cell disease. With a market cap of $550m and nearly $300m in cash, the future value of Fulcrum's pipeline remains uncertain amidst intense competition. Read the full article on Seeking AlphaAnaliz Makalesi • Jul 12
Will Fulcrum Therapeutics (NASDAQ:FULC) Spend Its Cash Wisely?
Just because a business does not make any money, does not mean that the stock will go down. By way of example, Fulcrum...Analiz Makalesi • Feb 11
Fulcrum Therapeutics (NASDAQ:FULC) Is In A Good Position To Deliver On Growth Plans
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Analiz Makalesi • Oct 28
We Think Fulcrum Therapeutics (NASDAQ:FULC) Needs To Drive Business Growth Carefully
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Analiz Makalesi • Jul 11
We Think Fulcrum Therapeutics (NASDAQ:FULC) Needs To Drive Business Growth Carefully
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Analiz Makalesi • Nov 17
What You Need To Know About The Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Analyst Downgrade Today
The latest analyst coverage could presage a bad day for Fulcrum Therapeutics, Inc. ( NASDAQ:FULC ), with the analysts...Analiz Makalesi • Oct 18
We're Keeping An Eye On Fulcrum Therapeutics' (NASDAQ:FULC) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Analiz Makalesi • Aug 13
Newsflash: Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Analysts Have Been Trimming Their Revenue Forecasts
Today is shaping up negative for Fulcrum Therapeutics, Inc. ( NASDAQ:FULC ) shareholders, with the analysts delivering...Seeking Alpha • Aug 11
Fulcrum Therapeutics GAAP EPS of -$0.83 misses by $0.17, revenue of $1.9M misses by $1.06M
Fulcrum Therapeutics press release (NASDAQ:FULC): Q2 GAAP EPS of -$0.83 misses by $0.17. Revenue of $1.9M (-56.6% Y/Y) misses by $1.06M. As of June 30, 2022, cash, cash equivalents, and marketable securities were $169.0M, as compared to $218.2M as of December 31, 2021. Based on current operating plans, including successful implementation of the operational realignment, Fulcrum expects that its existing cash, cash equivalents, and marketable securities will be sufficient to enable it to fund its operating expenses and capital expenditure requirements into mid-2024.Seeking Alpha • Jul 11
Fulcrum Therapeutics says chief medical officer Christopher Morabito to leave
Fulcrum Therapeutics (NASDAQ:FULC) on Monday said its chief medical officer Christopher Morabito will be leaving the company effective July 13. FULC said its R&D president Judith Dunn will be the interim chief medical officer while the company searches for a new executive. FULC said Dunn had assumed direct oversight of all clinical activities and related functions. Prior to joining Fulcrum (FULC), Dunn had held multiple leadership positions including leading global clinical development for Roche (OTCQX:RHHBY) (OTCQX:RHHBF). FULC stock earlier closed -4.1% at $5.69.Seeking Alpha • Jul 05
Fulcrum begins dosing in late-stage study of losmapimod for rare muscle disorder
Fulcrum Therapeutics (NASDAQ:FULC) said the first patient was dosed in a phase 3 trial of losmapimod to treat Facioscapulohumeral Muscular Dystrophy (FSHD). FSHD is a rare progressive disorder characterized by muscle weakness and wasting and initially affects the face, shoulder blades and upper arms. The study, dubbed REACH, will enroll ~230 adults at over 30 sites in North America and Europe and evaluate losmapimod, given orally as a 15-mg tablet twice a day, against placebo. The company said that a phase 2 trial, called ReDUX4, showed that losmapimod was superior to placebo and slowed disease progression and helped maintain function in adults with FSHD.Seeking Alpha • Jun 27
Fulcrum Therapeutics: Value Loss On SCD Data Update Is Telling
Fulcrum lost hugely this month after announcing data from an early Sickle Cell Disease trial. The other program is also beset with issues. This does not look attractive to us right now.Analiz Makalesi • May 10
These Analysts Think Fulcrum Therapeutics, Inc.'s (NASDAQ:FULC) Sales Are Under Threat
Market forces rained on the parade of Fulcrum Therapeutics, Inc. ( NASDAQ:FULC ) shareholders today, when the analysts...Analiz Makalesi • Apr 09
Companies Like Fulcrum Therapeutics (NASDAQ:FULC) Are In A Position To Invest In Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Hissedar Getirileri
| FULC | US Pharmaceuticals | US Pazar | |
|---|---|---|---|
| 7D | -1.8% | 5.0% | 1.1% |
| 1Y | 2.0% | 44.3% | 28.7% |
Getiri vs. Endüstri: FULC geçen yıl % 44.3 oranında getiri sağlayan US Pharmaceuticals sektörünün gerisinde kaldı.
Getiri vs Piyasa: FULC geçen yıl % 28.7 oranında getiri sağlayan US Piyasasının altında performans gösterdi.
Fiyat Oynaklığı
| FULC volatility | |
|---|---|
| FULC Average Weekly Movement | 9.3% |
| Pharmaceuticals Industry Average Movement | 10.1% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.1% |
İstikrarlı Hisse Senedi Fiyatı: FULC son 3 ayda US piyasasına kıyasla önemli bir fiyat oynaklığı yaşamadı.
Zaman İçindeki Volatilite: FULC 'nin haftalık oynaklığı ( 9% ) son bir yıldır istikrarlı seyretti.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 2015 | 55 | Alex Sapir | www.fulcrumtx.com |
Klinik aşamada bir biyofarmasötik şirketi olan Fulcrum Therapeutics, Inc. Amerika Birleşik Devletleri'nde karşılanmamış tıbbi ihtiyacın yüksek olduğu alanlarda genetik olarak tanımlanmış hastalıkları olan hastaların yaşamlarını iyileştirmek için küçük moleküller geliştirmektedir. Klinik aşamadaki ürün adayı, orak hücre hastalığı ve beta-talasemi tedavisi için faz 1b klinik çalışmasında olan bir fetal hemoglobin indükleyicisi olan pociredir. Şirket ayrıca elmas-blackfan anemisi, Kemik İliği Yetmezliği Sendromları, yeni fetal hemoglobin indükleyicileri, fibrotik bozuklukların tedavisi için programlar keşfetmektedir.
Fulcrum Therapeutics, Inc. Temel Bilgiler Özeti
| FULC temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | US$437.78m |
| Kazançlar(TTM) | -US$76.12m |
| Gelir(TTM) | n/a |
0.0x
P/S Oranı-5.8x
F/K OranıFULC aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| FULC gelir tablosu (TTM) | |
|---|---|
| Gelir | US$0 |
| Gelir Maliyeti | US$56.78m |
| Brüt Kâr | -US$56.78m |
| Diğer Giderler | US$19.33m |
| Kazançlar | -US$76.12m |
Son Raporlanan Kazançlar
Mar 31, 2026
Sonraki Kazanç Tarihi
n/a
| Hisse başına kazanç (EPS) | -1.14 |
| Brüt Marj | 0.00% |
| Net Kâr Marjı | 0.00% |
| Borç/Özkaynak Oranı | 0% |
FULC uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünŞirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/05/24 16:16 |
| Gün Sonu Hisse Fiyatı | 2026/05/22 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Fulcrum Therapeutics, Inc. 17 Bu analistlerden 11, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| Dae Gon Ha | BTIG |
| Kristen Kluska | Cantor Fitzgerald & Co. |